This inventor holds 2 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Genentech, Inc.. Active years: 2009-2011.
Company Filing History:
Years Active: 2009-2011
Title: Max L Tejada: Innovator in Humanized Antibodies
Introduction
Max L Tejada is a prominent inventor based in Campbell, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of humanized anti-TGF-beta antibodies. With a total of 2 patents, his work has the potential to impact the treatment of various disorders, including cancer.
Latest Patents
Tejada's latest patents focus on humanized anti-TGF-beta antibodies. These antibodies are designed to provide methods for their preparation and use, specifically targeting TGF-beta disorders. The patents also include articles of manufacture that are intended for various applications involving these humanized antibodies.
Career Highlights
Throughout his career, Max L Tejada has worked with notable companies in the biotechnology sector, including Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.
Collaborations
Tejada has collaborated with esteemed colleagues, including Camellia W Adams and Napoleone Ferrara. These partnerships have further enhanced his research and development efforts in the field of humanized antibodies.
Conclusion
Max L Tejada's contributions to the field of biotechnology, particularly through his patents on humanized anti-TGF-beta antibodies, demonstrate his commitment to advancing medical science. His work continues to pave the way for innovative treatments for serious health conditions.